Fetus Programming and Long Active Outcomes, Interaction Between Mother, Placenta and Fetus in Perinatal and Methabolic Disbalansces-focusing Diabetic Pregnancies

January 4, 2026 updated by: Miroslava Gojnic Dugalic, University of Belgrade

Placental Weight and Surface as an Indicator of Placental Insufficiency and Adverse Perinatal Outcomes

The placenta is a temporary but essential organ that develops during pregnancy and supports the growth and survival of the fetus. It delivers oxygen and nutrients from the mother to the baby and removes waste products from the fetal circulation. Proper placental development and function are critical for a healthy pregnancy and good outcomes for both the mother and the newborn.

When the placenta does not grow or function properly, this condition is known as placental insufficiency. Placental insufficiency may lead to serious pregnancy complications, such as poor fetal growth, preterm birth, low birth weight, low Apgar scores, and increased risk of illness or death around the time of birth. In some cases, placental dysfunction may also contribute to maternal complications, including pregnancy-related hypertension.

Previous research has shown that simple physical characteristics of the placenta-such as its weight, size, thickness, and surface area-may reflect how well the placenta functions. Placentas that are smaller than expected for a given gestational age may indicate long-standing problems with blood flow between the mother and the fetus. However, these measurements are not yet routinely used as clinical markers of risk.

The purpose of this study was to examine whether placental weight, placental surface area, placental disk weight, and related histopathological changes are associated with adverse perinatal outcomes. The study included both healthy pregnant women and women with medical conditions known to affect pregnancy, such as hypertension, diabetes mellitus, and thrombophilia. Special attention was given to placentas classified as small for gestational age (SGA-P) compared with placentas appropriate for gestational age (AGA-P).

Study Overview

Study Type

Observational

Enrollment (Actual)

440

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Belgrade, Serbia
        • Clinic of Gynecology and Obstetrics, University Clinical Center of Serbia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Pregnant women with singleton pregnancies who delivered at the Clinic of Gynecology and Obstetrics, University Clinical Centre of Serbia. The study population includes both healthy pregnant women and women with maternal comorbidities such as hypertensive disorders, diabetes mellitus, and thrombophilia. Placentas were examined after delivery and classified according to placental weight for gestational age.

Description

Inclusion Criteria: Pregnant women who delivered at the Clinic of Gynecology and Obstetrics, University Clinical Centre of Serbia

  • Singleton pregnancy
  • Available placental examination after delivery
  • Available clinical and perinatal outcome data
  • Gestational age at delivery ≥24 weeks

Exclusion Criteria:

Multiple pregnancy (e.g., twins or higher-order gestations)

  • Major congenital or chromosomal fetal anomalies
  • Intrauterine fetal demise
  • Conditions directly affecting placental weight (e.g., placental mosaicism)
  • Incomplete clinical, placental, or histopathological data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Appropriate-for-Gestational-Age Placenta (AGA-P)
regnant women whose placentas had a weight between the 10th and 90th percentile for gestational age.
observational study
Small-for-Gestational-Age Placenta (SGA-P)
Pregnant women whose placentas had a weight below the 10th percentile for gestational age.
observational study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Adverse perinatal outcome defined as at least one of the following: delivery before 34 gestational weeks, birth weight below 2200 g, or Apgar score <7 at 5 minutes.
Time Frame: From delivery to 5 minutes after birth
From delivery to 5 minutes after birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2025

Primary Completion (Actual)

January 4, 2026

Study Completion (Actual)

January 4, 2026

Study Registration Dates

First Submitted

January 4, 2026

First Submitted That Met QC Criteria

January 4, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 4, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1880/6

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Placental Insufficiency Hypertensive Disorders of Pregnancy Diabetes Mellitus in Pregnancy Thrombophilia in Pregnancy Adverse Perinatal Outcomes

Clinical Trials on No intervention (observational study)

Subscribe